Asset Publisher

Research, Chagas

TESEO

New chemotherapy regimens and biomarkers for Chagas Disease

Duration
01/2019 -
Coordinator
Igor Almeida, UTEP; Faustino Torrico, CEADES; Joaquím Gascón, ISGlobal
Funded by
U.S. National Institutes of Health (NIH)

Current approved treatments for Chagas disease (benznidazol, BZN and nifurtimos, NFX) were developed in the 1970s. The efficacy of both treatments in Chagas patients varies according to the stage of the diseases, the drug doses, the age of the patient and the strain of Trypanosoma cruzi, the parasite that causes the disease.   

In patients with chronic disease, these drugs fail in around 20% of cases and have a high frequency of adverse events. Recent data suggests that the drugs could be used at lower frequencies while maintaining the anti-parasitic effect.

Objectives

 This project proposes to test new dose regimens for these two old drugs. It has two main objectives:

  • Determine if the efficacy of BZN or NFX is maintained when reducing the dose or treatment duration (to 30 or 15 days) and/or whether the efficacy improves when increasing it from 60 to 90 days.
  • Evaluate new potential biomarkers of response to treatment and parasite elimination. Two types of biomarkers will be assessed: those derived from the host (anti-parasite antibodies) and those derived from the parasite (proteins secreted by the parasite).   

The project also has a series of secondary objectives, including: measure the reduction in parasite burden during the treatment, evaluate the serological response, characterize the pharmacokinetics of both drugs, evaluate the parasite genotype in patients that do not respond to treatment.   

Clinical trial

 This will be an open, randomized, prospectiva, observational phase 2 clinical trial with 6 parallel groups: three will receive different regimens of BZN and three will receive different regimens of NFX. 

Parasite clearance will be determined by molecular methods before, during and at different time points after the treatment.  

The study will be performed in Bolivia, in three sites (Cochabamba, Tarija y Sucre) of the Platform for the Comprehensive Care of Adult Chagas Patients.

Participating Institutions:

CEADES, Bolivia; University of El Paso, Texas, US; ISGlobal, Spain; Institute of Parasitology and Biomedicine López Neyra, Granada, Spain; Federal Drug Administration (FDA), Bethesda, US.

 

Our Team

Co-Investigador Principal

  • Quim Gascon
    Quim Gascon Research Professor, Director of the Chagas Initiative

Other projects

See Past Projects

MESA

Sharing knowledge and catalyzing research towards a malaria-free world

NHEPACHA

New Tools for the Diagnosis and Evaluation of Chagas Disease

RTS,S Vaccine Immunology Study

Study of immune correlates of protection against malaria after vaccination with RTS,S/AS01E: a comprehensive immunological arm of a Phase III double-blind, randomized, controlled multi-center trial

Euroleish.net

Control of Leishmaniasis. From bench to bedside and community

GREPIMER

Grup de recerca en patología importada i malaties emergents i re-emergents

ASINTMAL

Unravelling Disease Tolerance and Host Resistance in Afebrile 'P. falciparum' Infections: a Prospective Study in Mozambican Adults

ADAM

Malaria mass and focal drug administration to advance malaria elimination in Mozambique: accelerating programmatic implementation and policy translation

MULTIPLY

MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention

Science4Pandemics

Citizens engagement digital platform for collective intelligence in pandemics

HIDDENVIVAX

Novel organ-on-a-chip technology to study extracellular vesicles-mediated cryptic infections in Plasmodium vivax malaria

MENA Migrant Health

Transforming data collection and surveillance to drive migrant health research, care and policy

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

SMART

Identifying Severe Malaria with a new Aptamer-based Rapid diagnostic Test

MalTransc

Transcriptional regulation of adaptation and developmental decisions in malaria parasites: from epigenetic variation to directed transcriptional responses

GenMoz

P. falciparum genomic intelligence in Mozambique

BOHEMIA

Broad One Health Endectocide-based Malaria Intervention in Africa

RESPONSE

Mechanisms of the transcriptional responses to changes in the environment in the malaria parasite Plasmodium falciparum

VivaxEVTalk

Extracellular Vesicles as Intercellular Communicators and Biomarkers of Cryptic Erythrocytic Infections in Plasmodium vivax malaria

VaMonoS

Unravelling the heterogoneity and function of monocytes in vaccination and immunity to malaria

CLIMSOCTRYPBOL

Insight on climate and social participatory research for integral management of vectorborne zoonosis caused by Trypanosoma cruzi and Leishmania spp. in the Bolivian Gran Chaco.

SexMal

Social affairs and sex in P. falciparum: implications for malaria elimination